Pancreatic Cancer Research
Pancreatic cancer is the fifth leading cause of cancer death in Western societies, with a five year survival rate of less than 5%. The treatment and survival of patients with pancreatic cancer has not changed for over thirty years because there has been little research into the molecular and cell biology associated with it.
Our projects focus on translating basic scientific discoveries into the clinic. These include:
- Defining clinically and biologically relevant phenotypes of pancreatic cancer, primarily through our integral role in the Australian Pancreatic Cancer Genome Initiative (see below)
- Developing biomarkers of prognosis and therapeutic responsiveness with clinical utility
- Understanding molecular mechanisms of resistance to develop novel therapeutic strategies
Australian Pancreatic Cancer Genome Initiative (APGI)
The Australian Pancreatic Cancer Genome Initiative is a member of the International Cancer Genome Consortium (ICGC), a worldwide collaborative effort to comprehensively catalogue the genomic and transcriptomic abnormalities in over 50 major human cancers. Pancreatic Cancer was named as Australia’s major contribution to the ICGC, and the work of the APGI is providing unprecedented new insights into the molecular biology of pancreatic cancer, and helping promote research in development of new cancer treatments that are tailored towards individual patients. The APGI brings together expertise of pancreatic cancer scientists and health professionals across 15 clinical sites and academic institutions in Australia, and is dedicated to improving outcomes for pancreatic cancer patients and their families.
In the News
International team reveals 21 ‘signatures’ in 30 common cancers - Aug 15, 2013
Helping pancreatic cancer surgeons make tiebreaker decisions - Apr 15, 2011
Unmasking the deadly secrets of pancreatic cancer - Oct 25, 2012
Pancreatic Cancer Research Group wins Cancer Institute NSW award - Jul 30, 2012